Global Search | Novartis United States of America

Sort by

Relevance

Newest first

Oldest first

Hide Filters

Showing 877 results

Media Release / Feb 24, 2013

Novartis Reports Omalizumab Significantly Improved Chronic Idiopathic Urticaria Symptoms in Patients Who Failed Standard Therapy
Media Release / Feb 15, 2013

Novartis drug Zortress® is first in over a decade approved by FDA to prevent organ rejection in adult liver transplant patients
Media Release / Jan 23, 2013

Novartis drug Exjade® first treatment approved by FDA for chronic iron overload in patients with non-transfusion-dependent thalassemia
Media Release / Dec 19, 2012

NEJM published study shows Novartis compound ACZ885 significantly relieves symptoms in patients with serious form of childhood arthritis
Media Release / Dec 15, 2012

Multimedia Assets: Novartis drug Signifor® gains FDA approval as the first medication to treat Cushing's disease, a serious endocrine disorder
Media Release / Dec 14, 2012

Novartis drug Signifor® gains FDA approval as the first medication to treat Cushing's disease, a serious endocrine disorder
Media Release / Nov 07, 2012

Novartis Phase III study shows RLX030 improved symptoms and reduced deaths by one-third in patients with acute heart failure
Media Release / Oct 16, 2012

Leeza Gibbons joins Novartis to improve caregiving experience for millions of Americans through real-world peer advice on AlzheimersDisease.com
Q&A: Answering your questions about PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan) supply
Story / May 12, 2021

At-home app helps patients stay engaged and adherent to vision monitoring remotely

Education and Awareness

Novartis begins U.S. pilot program for OdySight, a clinically tested mobile application designed to help monitor vision remotely.

‹ Previous page
1
…
51
52
53
54
55
56
57
…
88
› Next page